Journal of Clinical Oncology, Vol 25, No 35 (December 10), 2007: pp. 5578-5583
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.13.5392
Panel of Serum Biomarkers for the Diagnosis of Lung Cancer
Edward F. Patz, Jr,
Michael J. Campa,
Elizabeth B. Gottlin,
Irina Kusmartseva,
Xiang Rong Guan,
James E. Herndon, II
From the Departments of Radiology, Biostatistics and Bioinformatics, and Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC
Address reprint requests to Edward F. Patz Jr, MD, Department of Radiology, Duke University Medical Center, Box 3808, Durham, NC 27710; e-mail: patz0002{at}mc.duke.edu
Purpose Currently, a blood test for lung cancer does not exist. Serum biomarkers that could aid clinicians in making case management decisions would be enormously valuable. We used two proteomic platforms and a literature search to select candidate serum markers for the diagnosis of lung cancer.
Methods We initially assayed six serum proteins, four discovered by proteomics and two previously known to be cancer associated, on a training set of sera from 100 patients (50 with a new diagnosis of lung cancer and 50 age- and sex-matched controls). Classification and Regression Tree (CART) analysis selected a panel of four markers that most efficiently predicted which patients had lung cancer. An independent, blinded validation set of sera from 97 patients (49 lung cancer patients and 48 matched controls) determined the accuracy of the four markers to predict which patients had lung cancer.
Results Four serum proteins—carcinoembryonic antigen, retinol binding protein, 1-antitrypsin, and squamous cell carcinoma antigen—were collectively found to correctly classify the majority of lung cancer and control patients in the training set (sensitivity, 89.3%; specificity, 84.7%). These markers also accurately classified patients in the independent validation set (sensitivity, 77.8%; specificity, 75.4%). Remarkably, 90% of patients who fell into any one of three groupings in the CART analysis had lung cancer.
Conclusion This panel of four serum proteins is valuable in suggesting the diagnosis of lung cancer. These data may be useful for treating patients with an indeterminate pulmonary lesion, and potentially in predicting individuals at high risk for lung cancer.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
I. Horvath, Z. Lazar, N. Gyulai, M. Kollai, and G. Losonczy
Exhaled biomarkers in lung cancer
Eur. Respir. J.,
July 1, 2009;
34(1):
261 - 275.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Yee, M. D. Sadar, D. D. Sin, M. Kuzyk, L. Xing, J. Kondra, A. McWilliams, S.F. P. Man, and S. Lam
Connective Tissue-Activating Peptide III: A Novel Blood Biomarker for Early Lung Cancer Detection
J. Clin. Oncol.,
June 10, 2009;
27(17):
2787 - 2792.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Findeisen, M. Zapatka, T. Peccerella, H. Matzk, M. Neumaier, D. Schadendorf, and S. Ugurel
Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic Profiling
J. Clin. Oncol.,
May 1, 2009;
27(13):
2199 - 2208.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Ocak, P. Chaurand, and P. P. Massion
Mass Spectrometry-based Proteomic Profiling of Lung Cancer
Proceedings of the ATS,
April 15, 2009;
6(2):
159 - 170.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. P. Mills, H. C. Furr, and S. A. Tanumihardjo
Retinol to Retinol-Binding Protein (RBP) Is Low in Obese Adults due to Elevated apo-RBP
Experimental Biology and Medicine,
October 1, 2008;
233(10):
1255 - 1261.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. S. Herbst, J. V. Heymach, and S. M. Lippman
Lung Cancer
N. Engl. J. Med.,
September 25, 2008;
359(13):
1367 - 1380.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Dubey and C. A. Powell
Update in Lung Cancer 2007
Am. J. Respir. Crit. Care Med.,
May 1, 2008;
177(9):
941 - 946.
[Full Text]
[PDF]
|
 |
|
|